Comparison of systemic adverse events associated with intravitreal anti-vegf injection: Ranibizumab versus bevacizumab

Journal of Korean Medical Science

Volumn 27, Issue 12, 2012, Pages 1580-1585

  Hwang, Duck Jin ^a   Kim, Yong Woo ^b   Woo, Se Joon ^a   Park, Kyu Hyung ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

Author keywords

Adverse drug event; Bevacizumab; Intravitreal injections; Ranibizumab

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; RANIBIZUMAB;

ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BRAIN INFARCTION; COMPARATIVE STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RETINA DISEASE; RETROSPECTIVE STUDY; RISK; VERY ELDERLY;

ADVERSE DRUG EVENT; BEVACIZUMAB; INTRAVITREAL INJECTIONS; RANIBIZUMAB;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CEREBRAL INFARCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RETINAL DISEASES; RETROSPECTIVE STUDIES;

EID: 84872506674     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2012.27.12.1580     Document Type: Article

References (27)

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
2. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 623.
3. Steinbrook R. The price of sight: ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355: 1409-12.
4. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
5. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007; 41: 614-25.
6. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-70.
7. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
8. Schmucker C, Loke YK, Ehlken C, Agostini HT, Hansen LL, Antes G, Lelgemann M. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Ophthalmol 2011; 95: 308-17.
9. Carneiro AM, Barthelmes D, Falcão MS, Mendonça LS, Fonseca SL, Gonçalves RM, Faria-Correia F, Falcão-Reis FM. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 2011; 225: 211-21.
10. Mitchell P, Korobelnik JF, Lanzetta P, Holz FG, Prünte C, Schmidt-Erfurth U, Tano Y, Wolf S. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94: 2-13.
11. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344-9.
12. Sheybani A, Kymes S, Schlief S, Apte R. Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab. Retina 2009; 29: 1404-8.
13. Alexander SL, Linde-Zwirble WT, Werther W, Depperschmidt EE, Wilson LJ, Palanki R, Saroj N, Butterworth SL, Ianchulev T. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 2007; 114: 2174-8.
14. Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010; 128: 1273-9.
15. Nguyen-Khoa BA, Goehring EL Jr, Werther W, Gower EW, Do DV, Jones JK. Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. Arch Ophthalmol 2008; 126: 1280-6.
16. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-9.
17. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 2010; 49: 287-97.
18. Ziemssen F, Zhu Q, Peters S, Grisanti S, El Wardani M, Szurman P, Bartz-Schmidt KU, Ziemssen T. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2009; 29: 213-24.
19. Genetech I. Lucentis (ranibizumab injection) Full prescribing information. June 2010.
20. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007; 114: 1179-85.
21. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007; 125: 1357-61.
22. Hahn R, Sacu S, Michels S, Varga A, Weigert G, Geitzenauer W, Vécsei-Marlovits P, Schmidt-Erfurth U. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration. Ophthalmologe 2007; 104: 588-93.
23. Sacu S, Michels S, Prager F, Weigert G, Dunavoelgyi R, Geitzenauer W, Pruente C, Schmidt-Erfurth U. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: longterm results. Eye (Lond) 2009; 23: 2223-7.
24. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908.
25. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-98.
26. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399-411.
27. Rosenfeld PJ. Bevacizumab versus ranibizumab for AMD. N Engl J Med 2011; 364: 1966-7.